Cue Biopharma, Inc. (CUE)

Cue Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-49.97	-50.73	-53.01	-44.16	-44.78	-36.7
Depreciation & Amortization	4.11	3.44	1.81	1.26	1.06	0.81
Share-Based Compensation	8.13	8.18	9.5	11.52	10.48	6.52
Other Operating Activities	-1.18	-0.84	-0.1	-7.45	0.75	-1.43
Operating Cash Flow	-38.91	-39.96	-41.81	-38.84	-32.49	-30.8
Capital Expenditures	-0.06	0	-0.17	-0.89	-0.6	0.08
Change in Investments	10	25	-24.45	10	5.05	3.37
Investing Cash Flow	9.95	25	-24.61	9.11	4.46	3.45
Share Issuance / Repurchase	16.83	13.86	44	19.98	58.89	50.79
Debt Issued / Paid	-3	-2	9.86	0	0	0
Other Financing Activities	-	-	-0.2	-0.75	-0.27	-
Financing Cash Flow	13.83	11.86	53.66	19.23	58.61	50.79
Net Cash Flow	-15.14	-3.1	-12.76	-10.5	30.58	23.44
Free Cash Flow	-38.97	-39.96	-41.97	-39.73	-33.09	-30.72
Free Cash Flow Margin	-555.09%	-727.85%	-3371.16%	-265.90%	-1049.01%	-888.17%
Free Cash Flow Per Share	-0.79	-0.87	-1.18	-1.27	-1.15	-1.39

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).